ArticleMediterranean journal of hematology and infectious diseases2020
Preliminary Data on COVID-19 in Patients with Hemoglobinopathies: A Multicentre ICET-A Study.
Article in Mediterranean journal of hematology and infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Impact of the SARS-CoV-2 infection in individuals with sickle cell disease: an integrative review.Frontiers in medicine · 2023Pooled it
- COVID-19 and Hemoglobinopathies: A Systematic Review of Clinical Presentations, Investigations, and Outcomes.Frontiers in medicine · 2021Pooled it
- COVID- 19 in patients affected by red blood cell disorders, results from the European registry ERN-EuroBloodNet.Orphanet journal of rare diseases · 2025Article
- Article
- Nitric-oxide enriched plasma-activated water inactivates 229E coronavirus and alters antiviral response genes in human lung host cells.Bioactive materials · 2023Article
- Epidemiological Surveillance of SARSCov2 in β-Thalassemia Patients in the Last Two Years: Reinfection Rate, Insights and Future Challenges.Mediterranean journal of hematology and infectious diseases · 2023Article
- The inactivation and destruction of viruses by reactive oxygen species generated through physical and cold atmospheric plasma techniques: Current status and perspectives.Journal of advanced research · 2023Review
- Nonthermal Biocompatible Plasma Inactivation of Coronavirus SARS-CoV-2: Prospects for Future Antiviral Applications.Viruses · 2022Review
- International Society of Blood Transfusion survey of experiences of blood banks and transfusion services during the COVID-19 pandemic.Vox sanguinis · 2022Article
- Thalassaemia is paradoxically associated with a reduced risk of in-hospital complications and mortality in COVID-19: Data from an international registry.Journal of cellular and molecular medicine · 2022Article
- SARS-CoV-2 infection in patients with β-thalassemia: The French experience.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2022Article
- The overall impact of COVID-19 on healthcare during the pandemic: A multidisciplinary point of view.Health science reports · 2021Review
- Prognostic factors associated with COVID-19 related severity in sickle cell disease.Blood cells, molecules & diseases · 2021Article
- SARS-CoV-2 infection in patients with β-thalassemia: Experience from Lebanon.American journal of hematology · 2021Article
- Sickle cell disease and COVID-19: Susceptibility and severity.Pediatric blood & cancer · 2021Review
- COVID-19 in a pregnant patient with beta-thalassemia major: A case report.Clinical case reports · 2021Article
- Article
- First report of COVID-19 reinfection in a patient with beta thalassemia major.Clinical case reports · 2021Article
- Coronavirus Disease 2019 (COVID-19) Severity in Patients with Thalassemias: A Nationwide Iranian Experience.Mediterranean journal of hematology and infectious diseases · 2021Article
- COVID-19 and thalassemia beta major in splenectomized patient: Clinical case progression and literature review.Clinical case reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aims to investigate, retrospectively, the epidemiological and clinical characteristics, laboratory results, radiologic findings, and outcomes of COVID-19 in patients with transfusion-dependent β thalassemia major (TM), β-thalassemia intermedia (TI) and sickle cell disease (SCD).
designA total of 17 Centers, from 10 countries, following 9,499 patients with hemoglobinopathies, participated in the survey. MAIN OUTCOME DATA: Clinical, laboratory, and radiologic findings and outcomes of patients with COVID-19 were collected from medical records and summarized.
resultsA total of 13 patients, 7 with TM, 3 with TI, and 3 with SCD, with confirmed COVID-19, were identified in 6 Centers from different countries. The overall mean age of patients was 33.7±12.3 years (range:13-66); 9/13 (69.2%) patients were females. Six patients had pneumonia, and 4 needed oxygen therapy. Increased C-reactive protein (6/10), high serum lactate dehydrogenase (LDH; 6/10), and erythrocyte sedimentation rate (ESR; 6/10) were the most common laboratory findings. 6/10 patients had an exacerbation of anemia (2 with SCD). In the majority of patients, the course of COVID-19 was moderate (6/10) and severe in 3/10 patients. A 30-year-old female with TM, developed a critical SARS-CoV-2 infection, followed by death in an Intensive Care Unit. In one Center (Oman), the majority of suspected cases were observed in patients with SCD between the age of 21 and 40 years. A rapid clinical improvement of tachypnea/dyspnea and oxygen saturation was observed, after red blood cell exchange transfusion, in a young girl with SCD and worsening of anemia (Hb level from 9.2 g/dl to 6.1g/dl).
conclusionsThe data presented in this survey permit an early assessment of the clinical characteristics of COVID 19 in different countries. 70% of symptomatic patients with COVID- 19 required hospitalization. The presence of associated co-morbidities can aggravate the severity of COVID- 19, leading to a poorer prognosis irrespective of age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.